Current:Home > ContactFDA approves Opill, the first daily birth control pill without a prescription -TradeSphere
FDA approves Opill, the first daily birth control pill without a prescription
NovaQuant Quantitative Think Tank Center View
Date:2025-04-09 07:12:06
The Food and Drug Administration approved a daily oral contraceptive pill for use without a prescription on Thursday, a landmark event that comes as some U.S. states have sought to restrict access to birth control and abortion.
The move clears the way for Opill (norgestrel), which comes in tablet form, to be sold over the counter in a wide range of venues, from online markets to drug stores, convenience stores and grocery stores.
"Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, said in a statement.
When used as directed, she added, daily oral contraception such as Opill "is safe and is expected to be more effective than currently available nonprescription contraceptive methods in preventing unintended pregnancy."
Opill is made by Perrigo, which has its headquarters in Dublin. Opill is deemed a "progestin-only" pill, made with "a synthetic version of the hormone progesterone to prevent pregnancy," as NPR has reported, noting that most birth control pills also contain estrogen.
"Today marks a truly momentous day for women's health nationwide," said Perrigo President and CEO Patrick Lockwood-Taylor, adding that his company's product "has the potential to radically transform women's access to contraception."
As for when the pills — sold in boxes containing a 28-day supply — will hit the market, the FDA says the timeline is up to Perrigo. The company says the pills will be available in stores and online early in the first quarter of 2024. Pricing hasn't been released.
"Other approved formulations and dosages of other oral contraceptives will remain available by prescription only," the FDA said.
veryGood! (343)
Related
- The Daily Money: Spending more on holiday travel?
- British royals sprinkle star power on a grateful French town with up-and-down ties to royalty
- WWE 'Friday Night Smackdown' moving to USA Network in 2024, will air NBC primetime shows
- Shannen Doherty, battling cancer, gets emotional after standing ovation at Florida 90s Con
- A South Texas lawmaker’s 15
- Detroit Tigers hire Chicago Blackhawks executive Jeff Greenberg as general manager
- Iowa Gov. Kim Reynolds says her husband has lung cancer
- 2 JetBlue planes reportedly struck by lasers near Boston, FAA says
- Trump wants to turn the clock on daylight saving time
- Biden to announce new military aid package for Ukraine as Zelenskyy visits Washington
Ranking
- Louvre will undergo expansion and restoration project, Macron says
- Poker player Rob Mercer admits lying about having terminal cancer in bid to get donations
- Beshear says sports wagering is off to strong start in Kentucky, with the pace about to pick up
- Anheuser-Busch says it will no longer amputate the tails of Budweiser's Clydesdales
- Can Bill Belichick turn North Carolina into a winner? At 72, he's chasing one last high
- Man rescued dangling from California's highest bridge 700 feet above river
- 3-year-old dies while crossing Rio Grande
- Greek civil servants have stopped work in a 24-hour strike that is disrupting public transport
Recommendation
Toyota to invest $922 million to build a new paint facility at its Kentucky complex
Moose headbutts stomps woman, dog, marking 4th moose attack on Colorado hiker this year
96-year-old federal judge suspended from hearing cases after concerns about her fitness
Man dies after swarm of bees attacks him on porch of his own home
DoorDash steps up driver ID checks after traffic safety complaints
Indictment alleges man threatened mass shooting at Stanley Cup game in Las Vegas
Parents, are you overindulging your kid? This 4-question test can help you find out
No. 1 pick Bryce Young's NFL Offensive Rookie of the Year betting odds continue nosedive